98 related articles for article (PubMed ID: 20575039)
1. XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia.
Guillem VM; Cervantes F; Martínez J; Alvarez-Larrán A; Collado M; Camós M; Sureda A; Maffioli M; Marugán I; Hernández-Boluda JC
Am J Hematol; 2010 Jul; 85(7):482-6. PubMed ID: 20575039
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
[TBL] [Abstract][Full Text] [Related]
3. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M
J Clin Oncol; 2005 Jun; 23(18):4100-9. PubMed ID: 15867198
[TBL] [Abstract][Full Text] [Related]
4. [Correlation of XPC Ala499Val and Lys939Gln polymorphisms to risks of esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma].
Zhou RM; Li Y; Wang N; Zhang XJ; Dong XJ; Guo W
Ai Zheng; 2006 Sep; 25(9):1113-9. PubMed ID: 16965652
[TBL] [Abstract][Full Text] [Related]
5. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
6. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.
Maffioli M; Camós M; Gaya A; Hernández-Boluda JC; Alvarez-Larrán A; Domingo A; Granell M; Guillem V; Vallansot R; Costa D; Bellosillo B; Colomer D; Cervantes F
Leuk Res; 2011 Aug; 35(8):1014-9. PubMed ID: 21185600
[TBL] [Abstract][Full Text] [Related]
7. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
8. Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma: XPC polymorphisms modify smoking-related risk.
Huang WY; Berndt SI; Kang D; Chatterjee N; Chanock SJ; Yeager M; Welch R; Bresalier RS; Weissfeld JL; Hayes RB
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):306-11. PubMed ID: 16492920
[TBL] [Abstract][Full Text] [Related]
9. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
10. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
[TBL] [Abstract][Full Text] [Related]
11. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.
Castagnetti F; Testoni N; Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo A; Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G
J Clin Oncol; 2010 Jun; 28(16):2748-54. PubMed ID: 20439635
[TBL] [Abstract][Full Text] [Related]
12. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
Marktel S; Marin D; Foot N; Szydlo R; Bua M; Karadimitris A; De Melo VA; Kotzampaltiris P; Dazzi F; Rahemtulla A; Olavarria E; Apperley JF; Goldman JM
Haematologica; 2003 Mar; 88(3):260-7. PubMed ID: 12651263
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis.
Li C; Hu Z; Liu Z; Wang LE; Strom SS; Gershenwald JE; Lee JE; Ross MI; Mansfield PF; Cormier JN; Prieto VG; Duvic M; Grimm EA; Wei Q
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2526-32. PubMed ID: 17164380
[TBL] [Abstract][Full Text] [Related]
15. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
16. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
[TBL] [Abstract][Full Text] [Related]
18. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique.
Kreuzer KA; Le Coutre P; Landt O; Na IK; Schwarz M; Schultheis K; Hochhaus A; Dörken B
Ann Hematol; 2003 May; 82(5):284-9. PubMed ID: 12692682
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
20. Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response.
Agirre X; Fontalba A; Andreu EJ; Odero MD; Larráyoz MJ; Montiel C; Calasanz MJ; Fernández-Luna JL; Prósper F
Haematologica; 2003 Dec; 88(12):1425-6. PubMed ID: 14687999
[No Abstract] [Full Text] [Related]
[Next] [New Search]
